$4.78
0.83% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US17248W3034
Symbol
CING
Sector
Industry

Cingulate Stock price

$4.78
+0.58 13.81% 1M
-2.23 31.79% 6M
-87.02 94.79% YTD
-43.10 90.02% 1Y
-633.62 99.25% 3Y
-1,063.22 99.55% 5Y
-1,063.22 99.55% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.04 0.83%
ISIN
US17248W3034
Symbol
CING
Sector
Industry

Key metrics

Market capitalization $15.35m
Enterprise Value $5.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.21
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-16.23m
Free Cash Flow (TTM) Free Cash Flow $-17.13m
Cash position $10.04m
EPS (TTM) EPS $-85.79
P/E forward negative
Short interest 3.49%
Show more

Is Cingulate a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Cingulate Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cingulate:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cingulate:

Buy
100%

Financial data from Cingulate

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.67 0.67
20% 20%
-
-0.67 -0.67
20% 20%
-
- Selling and Administrative Expenses 4.80 4.80
30% 30%
-
- Research and Development Expense 10 10
19% 19%
-
-16 -16
22% 22%
-
- Depreciation and Amortization 0.67 0.67
20% 20%
-
EBIT (Operating Income) EBIT -16 -16
21% 21%
-
Net Profit -16 -16
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cingulate directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cingulate Stock News

Neutral
GlobeNewsWire
6 days ago
KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc.  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5 million.
Neutral
GlobeNewsWire
about 2 months ago
On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301 On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301
Neutral
GlobeNewsWire
3 months ago
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast...
More Cingulate News

Company Profile

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.

Head office United States
CEO Shane Schaffer
Employees 13
Founded 2013
Website www.cingulate.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today